Treatment with an HDAC inhibitor activates varying molecular mechanisms that can lead to either the activation or suppression of autophagy [44, 45] To our knowledge, our study is the first to report the role of autophagy in regulating sensitivity to the combination of HDAC and proteasome inhibitors in gynecologic cancers. The gene discussed is HDAC9; the disease is female reproductive organ cancer.